Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 66
Filter
1.
Hum Exp Toxicol ; 40(1): 71-80, 2021 Jan.
Article in English | MEDLINE | ID: mdl-32748667

ABSTRACT

Methylphenidate (MPH) is used as the first-line treatment for attention-deficit hyperactivity disorder. However, there are concerns that this treatment may be associated with increased risk of retinal damage. This study was to investigate cytotoxicity of MPH on photoreceptor cells and explore its underlying mechanisms. MPH-caused cell toxicity was established in 661 W cells. Cytotoxicity was evaluated by 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium-bromid and lactate dehydrogenase assays. Oxidative stress was measured by the markers: glutathione (GSH) reductase, catalase, and superoxide dismutase activities as well as GSH, reactive oxygen species, and malondialdehyde levels. Gene and protein expression was detected by real-time polymerase chain reaction (PCR) and western blot, respectively. Results showed that MPH decreased 661 W cell viability, increased caspase-3/9 activities, and induced oxidative stress. Furthermore, MPH treatment increased messenger RNA (mRNA) expression of Beclin-1 and microtubule-associated protein 1A/1B-light chain 3B (LC3B) protein expression in 661 W cells, suggesting autophagy was induced. MPH treatment also upregulated p-JAK1/p-STAT1 protein expression. These data demonstrated that MPH could increase oxidative stress in photoreceptor cells to cause cell toxicity via autophagy, providing the scientific rationale for the photoreceptor cell damage caused by the MPH administration.


Subject(s)
Methylphenidate/toxicity , Photoreceptor Cells/drug effects , Animals , Autophagy , Glutathione , Malondialdehyde , Oxidative Stress , Reactive Oxygen Species
2.
Zhonghua Kou Qiang Yi Xue Za Zhi ; 55(9): 677-678, 2020 Sep 09.
Article in Chinese | MEDLINE | ID: mdl-32878405
3.
Int J Oral Maxillofac Surg ; 45(9): 1142-6, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27184354

ABSTRACT

The aim of this study was to provide reference information for implantology and chin bone harvesting in people of Han Chinese ethnicity by studying the mandibular incisive canal (MIC) using cone beam computed tomography (CBCT). Fifty subjects were included in the study. CBCT scans were obtained for all subjects, and 22 also underwent panoramic radiography to evaluate the visibility of the MIC. The CBCT data of the 50 subjects were reconstructed to measure MIC diameter, length, and location within the mandible. A MIC was identified in 38.6% of panoramic radiographs, with good clarity in 13.6%, while a MIC was identified in 100% of CBCT images, with good clarity in 63.6%. The diameter of the MIC decreased from origin to end. The left and right average MIC lengths were 17.84mm and 17.73mm, respectively. The MIC was close to the buccal cortical border and lower margin of the mandible. In conclusion, the MIC is an anatomical structure in the mandible that can be identified reliably with CBCT. On insertion, implants should be inclined slightly towards the lingual aspect of the anterior mandible to protect the MIC. The chin bone harvesting depth should be limited to 4mm; the harvesting site can be adjusted to the region above or below the MIC.


Subject(s)
Cone-Beam Computed Tomography , Mandible/anatomy & histology , Mandible/diagnostic imaging , Radiography, Panoramic , Adult , China/ethnology , Dental Implantation , Female , Humans , Male , Mandible/surgery , Retrospective Studies , Tissue and Organ Harvesting/methods
4.
Methods Inf Med ; 54(6): 560-7, 2015.
Article in English | MEDLINE | ID: mdl-26548400

ABSTRACT

INTRODUCTION: This article is part of the Focus Theme of Methods of Information in Medicine on "Big Data and Analytics in Healthcare". BACKGROUND: Hospital readmissions raise healthcare costs and cause significant distress to providers and patients. It is, therefore, of great interest to healthcare organizations to predict what patients are at risk to be readmitted to their hospitals. However, current logistic regression based risk prediction models have limited prediction power when applied to hospital administrative data. Meanwhile, although decision trees and random forests have been applied, they tend to be too complex to understand among the hospital practitioners. OBJECTIVES: Explore the use of conditional logistic regression to increase the prediction accuracy. METHODS: We analyzed an HCUP statewide inpatient discharge record dataset, which includes patient demographics, clinical and care utilization data from California. We extracted records of heart failure Medicare beneficiaries who had inpatient experience during an 11-month period. We corrected the data imbalance issue with under-sampling. In our study, we first applied standard logistic regression and decision tree to obtain influential variables and derive practically meaning decision rules. We then stratified the original data set accordingly and applied logistic regression on each data stratum. We further explored the effect of interacting variables in the logistic regression modeling. We conducted cross validation to assess the overall prediction performance of conditional logistic regression (CLR) and compared it with standard classification models. RESULTS: The developed CLR models outperformed several standard classification models (e.g., straightforward logistic regression, stepwise logistic regression, random forest, support vector machine). For example, the best CLR model improved the classification accuracy by nearly 20% over the straightforward logistic regression model. Furthermore, the developed CLR models tend to achieve better sensitivity of more than 10% over the standard classification models, which can be translated to correct labeling of additional 400 - 500 readmissions for heart failure patients in the state of California over a year. Lastly, several key predictor identified from the HCUP data include the disposition location from discharge, the number of chronic conditions, and the number of acute procedures. CONCLUSIONS: It would be beneficial to apply simple decision rules obtained from the decision tree in an ad-hoc manner to guide the cohort stratification. It could be potentially beneficial to explore the effect of pairwise interactions between influential predictors when building the logistic regression models for different data strata. Judicious use of the ad-hoc CLR models developed offers insights into future development of prediction models for hospital readmissions, which can lead to better intuition in identifying high-risk patients and developing effective post-discharge care strategies. Lastly, this paper is expected to raise the awareness of collecting data on additional markers and developing necessary database infrastructure for larger-scale exploratory studies on readmission risk prediction.


Subject(s)
Decision Support Systems, Clinical/organization & administration , Heart Failure/epidemiology , Heart Failure/therapy , Hospital Information Systems/statistics & numerical data , Patient Readmission/statistics & numerical data , Regression Analysis , California , Computer Simulation , Data Mining/methods , Heart Failure/diagnosis , Hospital Information Systems/classification , Humans , Logistic Models , Longitudinal Studies , Natural Language Processing , Reproducibility of Results , Risk Factors , Sensitivity and Specificity , Vocabulary, Controlled
5.
J Appl Microbiol ; 116(6): 1642-56, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24905221

ABSTRACT

AIMS: Starter lactic acid bacteria in Cheddar cheese face physico-chemical stresses during manufacture and ageing that alter their abilities to survive and to interact with other bacterial populations. Nonstarter bacteria are derived from milk handling, cheese equipment and human contact during manufacture. Probiotic bacteria are added to foods for human health benefits that also encounter physiological stresses and microbial competition that may mitigate their survival during ageing. We added probiotic Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei and Bifidobacterium animalis subsp. lactis to full-fat, reduced-fat and low-fat Cheddar cheeses, aiming to study their survival over 270 days of ageing and to determine the role of the cheese matrix in their survival. METHODS AND RESULTS: Probiotic and other lactic acid bacterial populations were enumerated by quantitative PCR using primers specifically targeting the different bacterial genera or species of interest. Bifidobacteria were initially added at 10(6) CFU g(-1) cheese and survived variably in the different cheeses over the 270-day ageing process. Probiotic lactobacilli that were added at 10(7) CFU g(-1) cheese and incident nonstarter lactobacilli (initially at 10(8) CFU g(-1) cheese) increased by 10- to 100-fold over 270 days. Viable bacterial populations were differentiated using propidium monoazide followed by species-specific qPCR assays, which demonstrated that the starter and probiotic microbes survived over ageing, independent of cheese type. Addition of probiotic bacteria, at levels 100-fold below that of starter bacteria, modified starter and nonstarter bacterial levels. CONCLUSIONS: We demonstrated that starter lactococci, nonstarter lactobacilli and probiotic bacteria are capable of surviving throughout the cheesemaking and ageing process, indicating that delivery via hard cheeses is possible. Probiotic addition at lower levels may also alter starter and nonstarter bacterial survival. SIGNIFICANCE AND IMPACT OF THE STUDY: We applied qPCR to study multispecies survival and viability and distinctly enumerated bacterial species in commercial-scale Cheddar cheese manufacture.


Subject(s)
Bifidobacterium/growth & development , Cheese/microbiology , Lactobacillus/growth & development , Probiotics , Animals , Bifidobacterium/isolation & purification , Colony Count, Microbial , Lactic Acid , Lactobacillus/isolation & purification , Microbial Viability , Milk/microbiology , Polymerase Chain Reaction
6.
Lupus ; 23(4): 436-42, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24399814

ABSTRACT

INTRODUCTION: Renal involvement is the most common serious complication in patients with systemic lupus erythematosus (SLE). OBJECTIVE: The objective of this article is to investigate and determine the associated factors of disease damage among lupus nephritis (LN) patients. METHODS: Medical records of LN patients who attended regular follow-up for at least one year in the Nephrology/SLE Clinic, Universiti Kebangsaan Malaysia Medical Centre (UKMMC), were reviewed. Their Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index scores were noted. Univariate analysis and multivariable regression analysis were performed to determine the independent factors of disease damage in LN. RESULTS: A total of 150 patients were included and their follow-up duration ranged from one to 20 years. Sixty (40%) LN patients had disease damage (SDI ≥1). In the univariate analysis, it was associated with age, longer disease duration, antiphospholipid syndrome (APS), higher maximum daily oral prednisolone dose (mg/day), lower mean C3 and C4, higher chronicity index and global sclerosis on renal biopsies (p < 0.05). Patients who received early (≤3 months after the SLE diagnosis) hydroxychloroquine (HCQ), optimum HCQ dose at 6.5 mg/kg/day and achieved early complete remission (CR) were less likely to have disease damage (p < 0.05). After adjustment for age, gender, disease duration and severity, multivariable regression analysis revealed that a higher maximum daily dose of oral prednisolone was independently associated with disease damage while early HCQ and CR were associated with lower disease damage. CONCLUSION: Higher maximum daily prednisolone dose predicted disease damage whereas treatment with early HCQ and early CR had a protective role against disease damage.


Subject(s)
Antiphospholipid Syndrome/epidemiology , Hydroxychloroquine/therapeutic use , Lupus Nephritis/physiopathology , Prednisolone/therapeutic use , Adult , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Humans , Hydroxychloroquine/administration & dosage , Lupus Nephritis/epidemiology , Malaysia/epidemiology , Male , Middle Aged , Multivariate Analysis , Prednisolone/administration & dosage , Regression Analysis , Remission Induction , Retrospective Studies , Risk Factors , Severity of Illness Index , Time Factors
7.
Cell Death Dis ; 4: e838, 2013 Oct 10.
Article in English | MEDLINE | ID: mdl-24113172

ABSTRACT

Induction of cell death and inhibition of cell survival are the main principles of cancer therapy. Resistance to chemotherapeutic agents is a major problem in oncology, which limits the effectiveness of anticancer drugs. A variety of factors contribute to drug resistance, including host factors, specific genetic or epigenetic alterations in the cancer cells and so on. Although various mechanisms by which cancer cells become resistant to anticancer drugs in the microenvironment have been well elucidated, how to circumvent this resistance to improve anticancer efficacy remains to be defined. Autophagy, an important homeostatic cellular recycling mechanism, is now emerging as a crucial player in response to metabolic and therapeutic stresses, which attempts to maintain/restore metabolic homeostasis through the catabolic lysis of excessive or unnecessary proteins and injured or aged organelles. Recently, several studies have shown that autophagy constitutes a potential target for cancer therapy and the induction of autophagy in response to therapeutics can be viewed as having a prodeath or a prosurvival role, which contributes to the anticancer efficacy of these drugs as well as drug resistance. Thus, understanding the novel function of autophagy may allow us to develop a promising therapeutic strategy to enhance the effects of chemotherapy and improve clinical outcomes in the treatment of cancer patients.


Subject(s)
Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Autophagy/drug effects , Drug Resistance, Neoplasm/drug effects , Neoplasms/drug therapy , Neoplasms/pathology , Cell Survival/drug effects , Humans , Stress, Physiological/drug effects
8.
Asian Pac J Cancer Prev ; 14(2): 747-52, 2013.
Article in English | MEDLINE | ID: mdl-23621231

ABSTRACT

Oncostatin M (OSM) is a multifunctional cellular regulator acting on a wide variety of cells, which has potential roles in the regulation of gene activation, cell survival, proliferation and differentiation. Previous studies have shown that OSM can induce morphological and/or functional differentiation and maturation of many tumor cells. However, the action of OSM on the induction of differentiation of human hepatocellular carcinoma (HCC) has not been reported. Here, we investigated the effects of different concentrations of OSM on human HCC cell line SMMC-7721 growth, proliferation, cell cycling, apoptosis and differentiation in vitro. Cell growth was determined via MTT assay, proliferation by cell cycle analysis, apoptosis by flow cytometry, morphology by transmission electronic microscopy, and cell function by detection of biochemical markers. Our results demonstrated that OSM strongly inhibited the growth of SMMC-7721 cells in a dose-dependent manner, associated with decreased clonogenicity. Cell cycle analysis revealed a decreased proportion of cells in S phase, with arrest at G0/G1. The apotosis rate was increased after OSM treatment compared to the control. These changes were associated with striking changes in cellular morphology, toward a more mature hepatic phenotype, accompanied by significant reduction of the expression of AFP and specific activity of γ-GT, with remarkable increase in secretion of albumin and ALP activity. Taken together, our findings indicate that OSM could induce the differentiation and reduce cell viability of SMMC-7721 cells, suggesting that differentiation therapy with OSM offers the opportunity for therapeutic intervention in HCC.


Subject(s)
Carcinoma, Hepatocellular/metabolism , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Liver Neoplasms/metabolism , Oncostatin M/pharmacology , Albumins/metabolism , Alkaline Phosphatase/metabolism , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Cycle/drug effects , Cell Line, Tumor , Cell Survival/drug effects , G1 Phase Cell Cycle Checkpoints/drug effects , Growth Inhibitors/pharmacology , Humans , alpha-Fetoproteins/metabolism
9.
Lupus ; 22(5): 492-6, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23435619

ABSTRACT

INTRODUCTION: Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disorder which is increasingly recognized to occur in systemic lupus erythematosus (SLE). OBJECTIVE: The purpose of this study was to identify the characteristics of SLE patients with PRES and the associated factors of the poor outcome among them. METHODS: We investigated SLE patients who developed PRES between 2005-2011 at the Universiti Kebangsaan Malaysia Medical Centre. A comprehensive literature search was done to find all published cases of PRES in SLE. Pooled analysis was conducted to identify the factors associated with poor outcome. RESULTS: There were 103 cases of PRES in SLE published in the literature but only 87 cases were included in the analysis in view of incomplete individual data in the remaining cases. The majority of the cases were Asians (74.2%), female (95.4%) with mean age of 26.3 ± 8.8 years. PRES was highly associated with active disease (97.5%), hypertension (91.7%) and renal involvement (85.1%). We found that 79 patients had a full recovery (90.8%) with a mean onset of full clinical recovery in 5.6 ± 4.1 days. On univariate analysis and logistic regression analysis the predictors of poor outcome, defined as incomplete clinical recovery or death, were intracranial hemorrhage, odds ratio (OR) 14 (1.1-187.2), p=0.04 and brainstem involvement in PRES, OR 10.9 (1.3-90.6), p=0.003. CONCLUSION: Intracranial hemorrhage and brainstem involvement were the two important predictors of poor outcome of PRES. Larger prospective studies are needed to further delineate the risk of poor outcome among them.


Subject(s)
Lupus Erythematosus, Systemic/complications , Posterior Leukoencephalopathy Syndrome/complications , Adolescent , Adult , Female , Humans , Logistic Models , Male , Retrospective Studies , Young Adult
10.
Reumatismo ; 64(6): 341-9, 2012 Dec 20.
Article in English | MEDLINE | ID: mdl-23285477

ABSTRACT

OBJECTIVES: To investigate the prevalence of thickened carotid intima media thickness (CIMT) and its associated risk factors in patients with lupus nephritis (LN) who were in remission. METHODS: This was a cross sectional study in which consecutive LN patients who were in remission and attending our Nephrology/SLE Clinic were included. Their demographic profile, traditional cardiovascular risk factors and treatment medications were evaluated by clinical interview and review of medical records. Carotid intima media thickness (CIMT) was measured using B Mode carotid ultrasonography. CIMT was considered to be abnormally thickened if it exceeded the 75th percentile matched for age-and sex-matched normal controls. The associated factors for thickened CIMT were examined. RESULTS: A total of 39 patients with a mean remission duration of 29 ± 24.3 months and on a mean prednisolone dose of 9.10 ± 7.83 mg daily completed the study. Six patients (15.4%) had thickened CIMT. On univariate analysis, male gender, patient age, older age at diagnosis, higher serum CRP levels, greater proteinuria and higher mean cumulative azathioprine dose were associated with thickened CIMT (P<0.05). Lower mean cumulative doses of cyclosporine A (CyA) and mycophenolic acid (MPA) (P<0.05) each were associated with thickened CIMT. Using regression analysis, the associated factors of CIMT were older age at diagnosis and proteinuria. CONCLUSIONS: Lupus factors particularly age at diagnosis and proteinuria were the associated factors of thickened CIMT. Larger prospective trials are indicated to confirm our findings.


Subject(s)
Atherosclerosis/pathology , Carotid Intima-Media Thickness , Lupus Nephritis/pathology , Adult , Atherosclerosis/ethnology , Atherosclerosis/etiology , Atherosclerosis/prevention & control , Carotid Artery, Common/pathology , China/ethnology , Comorbidity , Diabetes Mellitus/epidemiology , Dyslipidemias/epidemiology , Female , Humans , Hypertension/epidemiology , Immunosuppressive Agents , India/ethnology , Lupus Nephritis/complications , Lupus Nephritis/drug therapy , Lupus Nephritis/ethnology , Lupus Nephritis/urine , Malaysia/epidemiology , Male , Middle Aged , Prospective Studies , Proteinuria/etiology , Risk Factors , Tertiary Care Centers/statistics & numerical data , Young Adult
11.
IEEE Trans Vis Comput Graph ; 18(12): 2631-8, 2012 Dec.
Article in English | MEDLINE | ID: mdl-26357172

ABSTRACT

Reading a visualization can involve a number of tasks such as extracting, comparing or aggregating numerical values. Yet, most of the charts that are published in newspapers, reports, books, and on the Web only support a subset of these tasks. In this paper we introduce graphical overlays-visual elements that are layered onto charts to facilitate a larger set of chart reading tasks. These overlays directly support the lower-level perceptual and cognitive processes that viewers must perform to read a chart. We identify five main types of overlays that support these processes; the overlays can provide (1) reference structures such as gridlines, (2) highlights such as outlines around important marks, (3) redundant encodings such as numerical data labels, (4) summary statistics such as the mean or max and (5) annotations such as descriptive text for context. We then present an automated system that applies user-chosen graphical overlays to existing chart bitmaps. Our approach is based on the insight that generating most of these graphical overlays only requires knowing the properties of the visual marks and axes that encode the data, but does not require access to the underlying data values. Thus, our system analyzes the chart bitmap to extract only the properties necessary to generate the desired overlay. We also discuss techniques for generating interactive overlays that provide additional controls to viewers. We demonstrate several examples of each overlay type for bar, pie and line charts.

13.
Glob Public Health ; 5(1): 75-86, 2010.
Article in English | MEDLINE | ID: mdl-19479594

ABSTRACT

HIV/AIDS prevention efforts in Cambodia have largely focussed on urban populations. This focus, however, has diverted attention from the impact of the disease on rural communities, where poverty and a lack of basic infrastructure forced many to migrate to urban areas. Rural communities thus play a crucial part in the understanding of HIV/AIDS transmission dynamics in Cambodia. This paper will provide an analysis of socio-economic and health-related needs of rural communities in Cambodia, giving a different context for understanding the national burden of HIV/AIDS. These concepts will be illustrated with experiences from Project AID Khmer, a Cambodian non-governmental organisation that is working to improve Cambodian health through education programmes and community capacity building in rural Takeo province.


Subject(s)
HIV Infections/prevention & control , Health Care Coalitions/organization & administration , Health Education/organization & administration , Health Knowledge, Attitudes, Practice , Rural Health , Cambodia/epidemiology , Community-Institutional Relations , Family Health , Female , HIV Infections/epidemiology , Health Education/methods , Humans , Male , Organizational Case Studies , Poverty , Risk-Taking , Transients and Migrants , Urbanization/trends , Vulnerable Populations
14.
Scand J Rheumatol ; 38(4): 276-81, 2009.
Article in English | MEDLINE | ID: mdl-19306160

ABSTRACT

OBJECTIVES: The human urate transporter 1 (URAT1, encoded by SLC22A12) was recently identified as the major absorptive urate transporter protein in the kidney responsible for regulating blood urate levels. The present study was designed to investigate the rs893006 polymorphism (GG, GT, and TT) in SLC22A12 in a total of 292 Chinese male subjects. Differences of clinical characteristics among the genotype groups were analysed. METHODS: A total of 124 consecutive patients with diagnosis of primary gout and 168 healthy male volunteers were enrolled in this study. Demographic and clinical data were obtained from the patients and controls. DNA was purified from peripheral blood and the rs893006 polymorphism was determined with sequencing analysis. In addition, DNA samples were detected by high-resolution melting (HRM) analysis. Melting curves were analysed as fluorescence difference plots. The shift and curve shapes of melting profiles were used to distinguish the different genotypes. RESULTS: GG, GT, and TT genotypes were unambiguously distinguished with HRM technology. Genotyping based on HRM analysis was fully concordant with the sequencing. Serum uric acid levels in the TT genotype subjects were significantly lower than those in the GG and GT genotypes. However, no differences among the groups were found in body mass index (BMI), blood pressure, creatinine, total cholesterol, and triglycerides. The TT genotype was observed more frequently among the low uric acid group than the high uric acid group. CONCLUSIONS: HRM analysis is a simple, rapid and accurate one-tube assay for genotyping the SLCSSA12 gene. The rs893006 polymorphism in SLC22CA12 was confirmed to be a genetic risk for hyperuricaemia among the Chinese male population.


Subject(s)
Genetic Predisposition to Disease/epidemiology , Gout/epidemiology , Gout/genetics , Molecular Diagnostic Techniques/methods , Organic Anion Transporters/genetics , Organic Cation Transport Proteins/genetics , Polymorphism, Single Nucleotide/genetics , Adult , Aged , Analysis of Variance , Case-Control Studies , China/epidemiology , DNA Mutational Analysis , Genotype , Gout/diagnosis , Humans , Hyperuricemia/epidemiology , Hyperuricemia/genetics , Incidence , Inteins/genetics , Male , Middle Aged , Organic Anion Transporters/analysis , Polymerase Chain Reaction/methods , Probability , Risk Factors , Uric Acid/blood , Uric Acid/metabolism
15.
Singapore Med J ; 50(1): e32-4, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19224067

ABSTRACT

Drug-induced acute interstitial nephritis is a well-recognised and important reversible cause of acute renal failure. Peroxisome-proliferator activated receptor-gamma agonists, such as rosiglitazone, have been proven to be safe in chronic kidney disease patients. We describe a 65-year-old man with long-standing diabetes mellitus and hypertension, presenting with a five-day history of fluid overload and uraemic symptoms. There was no ingestion of analgesics, alternative medicine and other nephrotoxic drugs, the only new prescription being rosiglitazone, which was commenced during his last clinic follow-up two weeks prior to presentation. He required haemodialysis with minimal improvement in renal profile, despite cessation of the offending drug. Renal biopsy revealed findings consistent with acute interstitial nephritis. An episode of upper gastrointestinal bleeding with bleeding duodenal ulcer limited the use of steroids. He was treated with a course of mycophenolate mofetil which showed good gradual response and he remained stable with residual renal impairment.


Subject(s)
Acute Kidney Injury/chemically induced , Hypoglycemic Agents/adverse effects , Thiazolidinediones/adverse effects , Acute Kidney Injury/drug therapy , Aged , Humans , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/complications , Male , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Renal Dialysis , Rosiglitazone
16.
Lupus ; 18(2): 178-81, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19151123

ABSTRACT

The aim of this study was to assess the bone mineral density (BMD) of premenopausal patients with systemic lupus erythematosus (SLE) on corticosteroids (CS) and to determine the influence of CS and other risk factors on BMD. A total of 98 premenopausal patients with SLE were recruited from outpatient clinics in two teaching hospitals. Risk factors for osteoporosis were determined, and BMD was measured using dual-energy x-ray absorptiometry. The mean age of the patients was 30.05 +/- 7.54 years. The mean dose of prednisolone at time of BMD measurement was 18.38 +/- 10.85 mg daily. Median duration of CS use was 2.5 years (range 0-20). Median cumulative dose of CS was 9.04 g (range 0.28-890.0). Six patients (6.1%) had osteoporosis, 41 (41.9%) had osteopenia and 51 (52.0%) had normal BMD. Lumbar spine T score correlated with cumulative CS dose (P = 0.019). Duration of CS intake correlated with femoral neck T score (P = 0.04) and trochanter T score (P = 0.008). There was no correlation between BMD and race, SLE Disease Activity Index score, smoking and self-reported calcium intake or exercise. Only 52% of these patients had normal BMD. The duration and cumulative dose of CS intake was significantly correlated to BMD, but not the other commonly assessed risk factors. These findings suggest that premenopausal patients with SLE on CS should have their BMD measured at regular intervals to fully assess their osteoporosis risk.


Subject(s)
Adrenal Cortex Hormones/adverse effects , Bone Density , Lupus Erythematosus, Systemic/drug therapy , Osteoporosis/chemically induced , Premenopause , Adolescent , Adult , Cohort Studies , Female , Humans , Malaysia , Middle Aged , Young Adult
17.
Singapore Med J ; 49(11): 924-9, 2008 Nov.
Article in English | MEDLINE | ID: mdl-19037561

ABSTRACT

INTRODUCTION: Angiotensin-converting enzyme (ACE) gene polymorphism, especially the deletion/deletion (DD) genotype, is associated with the disease progression of immunoglobulin A (IgA) nephropathy patients in various studies from both Asia Pacific and European populations. However, recent studies within the same populations were unable to reproduce the same results. Hence, we had studied the distribution of the DD genotype, the association between ACE gene polymorphism and the disease progression, and the factors (other than ACE gene polymorphism) which were involved in the disease progression of our local patients. METHODS: This was a cross-sectional study of biopsy-proven IgA nephropathy patients attending the Nephrology Clinic, Hospital Universiti Kebangsaan Malaysia. Both biochemical and urine tests at the time of first presentation were compared to those at the time of the study, and the disease progression was analysed. The ACE gene polymorphism was identified via PCR-amplification technique, and patients were then categorised into the DD and the non-DD groups for detailed analysis. Histological severity of each renal biopsy was scored according to the predetermined criteria and medications used were recorded. The association between the gene polymorphism and disease progression was then determined. The patients who were stable or had renal function deterioration, were respectively regrouped into Groups 1 and 2, to identity those factors (other than ACE gene polymorphism), which were involved in the disease progression. RESULTS: 60 patients with adequate renal histopathological examination were recruited. Their mean age was 40.9 +/- 12.3 years and the follow-up duration was 4 +/- 3 years (range 6 months-20 years). More than two-thirds of them were treated with ACE inhibitors or angiotensin receptor blockers and 8.3 percent received the combination treatment. The DD genotype was noted in 13.3 percent of study patients, insertion/insertion in 48.3 percent and insertion/deletion genotype in 38.3 percent. Although the estimated glomerular filtration rate (eGFR) of both groups were the same during their initial presentation, the DD patients had more severe disease compared to the non-DD patients at the time of the study. Their serum creatinine and eGFR was 178 (IQR 31.3) micromol/L and 42.1 +/- 31.1 ml/min/1.73 square metres, whereas the non-DD patients had serum creatinine and eGFR of 79 (IQR: 88.3) micromol/L and 76.6 +/- 42.1 ml/min/1.73 square metres, respectively (p-value is less than 0.01). The DD patients were also found to have more severe vascular damage in their renal biopsies compared to the non-DD patients. The annual rate of decline in eGFR was not significantly different between the two groups. It was -5.7 +/- 2.2 ml/min/1.73 square metres/year for the DD group and -4.8 +/- 2.0 ml/min/1.73 square metres/year for the non-DD group (p-value is equal to 0.5). They also had severe proteinuria with UPCI of 0.09 (IQR 0.2) g/mmol creatinine vs. 0.04 (IQR 0.10) g/mmol creatinine (p-value is less than 0.01). The study also confirmed that patients who had higher systolic blood pressure, greater proteinuria and longer follow-up duration had significant renal function deterioration compared to those who did not. CONCLUSION: The DD genotype, although found in a minority of the patients, might have adversely affected the disease progression of our IgA nephropathy patients. Higher systolic blood pressure, greater proteinuria and longer follow-up duration were the other prognostic factors in IgA nephropathy patients. However, appropriate treatment, especially prompt use of renin-angiotensin-aldosterone system blockade, should stabilise the disease regardless of their genotype.


Subject(s)
Glomerulonephritis, IGA/genetics , Glomerulonephritis, IGA/pathology , Peptidyl-Dipeptidase A/genetics , Polymorphism, Genetic , Adult , Cross-Sectional Studies , Disease Progression , Female , Gene Deletion , Genotype , Glomerular Filtration Rate , Glomerulonephritis, IGA/diagnosis , Humans , Malaysia , Male , Middle Aged , Renin-Angiotensin System/genetics
18.
Kidney Int ; 73(7): 856-62, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18160963

ABSTRACT

Prehemodialysis and hemodialysis patients are at an increased risk of hepatitis B infection and have an impaired immune response to hepatitis B vaccines. We evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in this population. We measured antibody persistence for up to 42 months, and the anamnestic response and safety of booster doses in patients who were no longer seroprotected. The primary vaccination study showed that HBV-AS04 elicited an earlier antibody response and higher antibody titers than four double doses of standard hepatitis B vaccine. Seroprotection rates were significantly higher in HBV-AS04 recipients throughout the study. The decline in seroprotection over time was significantly less in the HBV-AS04 group with significantly fewer primed patients requiring a booster dose over the follow-up period. Solicited/unsolicited adverse events were rare following booster administration. Fifty-seven patients experienced a serious adverse event during the follow-up; none of which was vaccine related. When HBV-AS04 was used as the priming immunogen, the need for a booster dose occurred at a longer time compared to double doses of standard hepatitis B vaccine. Hence, in this population, the HBV-AS04 was immunogenic, safe, and well-tolerated both as a booster dose after HBV-AS04 or standard hepatitis B vaccine priming.


Subject(s)
Hepatitis B Surface Antigens/blood , Hepatitis B Vaccines/immunology , Hepatitis B/prevention & control , Lipid A/analogs & derivatives , Renal Dialysis , Adjuvants, Immunologic , Female , Follow-Up Studies , Humans , Lipid A/immunology , Male , Middle Aged , Time Factors
19.
Med J Malaysia ; 62(4): 329-34, 2007 Oct.
Article in English | MEDLINE | ID: mdl-18551939

ABSTRACT

The clinical outcome of bacteraemic patients is influenced by many factors. It is vital to know one's own local hospital epidemiological data so as to provide optimal care to the affected patients. This was a prospective, observational study carried out in the said patient population over a period of four months in the year 2005. One hundred and ninety one patients presented with bacteraemia over the study period. Fifty-two (27%) of the patients died. Mechanical ventilation, inappropriate empirical antibiotic usage, Chinese ethnicity and low serum albumin levels independently affected prognosis. These factors should alert physicians to those patients who require more intensive monitoring and care.


Subject(s)
Bacteremia/epidemiology , Albumins , Anti-Bacterial Agents/therapeutic use , Bacteremia/blood , Bacteremia/diagnosis , Decision Making , Female , Hospitals, Teaching , Humans , Malaysia/epidemiology , Male , Middle Aged , Prognosis , Respiration, Artificial , Risk Factors , Treatment Outcome
20.
Med J Malaysia ; 61(5): 633-5, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17623968

ABSTRACT

A 20-year-old girl first notice bilateral ocular muscle weakness in 2001. Two months later, she developed acute muscle paralysis and respiratory failure which required ventilation. Serum anti-acetylcholine receptor antibodies and repetitive nerve stimulation test was positive and consistent with myasthenia gravis (MG). CT scan thorax revealed thymic enlargement and she underwent a video assisted thymectomy (VATS). However, over the next three years, despite maximal doses of various immunosuppressive agents with plasmapheresis and intravenous immunoglobulin, she was admitted with recurrent myasthenic crisis without any obvious precipitant. She was then commenced on mycophenolate mofetil and together with regular plasmapheresis, cyclosporine and prednisolone, her symptoms have finally improved and brought under control.


Subject(s)
Immunoglobulins/therapeutic use , Immunosuppressive Agents/therapeutic use , Myasthenia Gravis/surgery , Thymectomy , Adult , Cyclosporine/therapeutic use , Female , Humans , Myasthenia Gravis/diagnosis , Myasthenia Gravis/drug therapy , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Plasmapheresis , Prednisolone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...